Biopreparations: current application prospects
Keywords:bacteriophages, lytical activity, virulence
Topicality. Taking into account the current state of infectious pathology, the emergence of new diseases, changes in biological properties in the already studied pathogens and the burdened course of infectious diseases, as well as taking into account the prevalence and rate of formation of antibiotic resistance, special attention is drawn to the bacteriophages. Control of the prevalence of infectious agents is achieved both through the use of effective antimicrobial agents and immunobiological drugs for prevention purposes.
Aim. To substantiate the perspective use of bacteriophages in creating immunoprophylactic agents.
Materials and methods. Appelman’s method and the method of double series dilutions were used in the research. Reference strains were used as a microbiological model: S. aureus АТСС 25923, Е. соlі АТСС 25922, В. subtilis АТСС 6633, Р. аеrugenosa 126/18, Pr. mirabilis 128/34, S. abony Dick 1,4,5,12, Str. pyogenes Dick-1.
Results and discussion. The conducted researches on studying the virulence of bacteriophages by means of determination of the lytical activity by the method of titration of a bacteriophage in a liquid nutrient medium (Appelman’s method) have established that the virulence of phages is characterized by the ability of directed lysis of morpho-anatomic structure of target bacteria. In addition, the dependence of the level of lithium titers of phages on the tinctorial characteristics of target bacteria was established: Gram-negative bacteria were 2 times less sensitive to the action of phages.
Conclusions. Obtained results of researches proved expediency of application of bacteriophages for immunoprophylactic purposes due to absence of side immunochemical effects.
World Health Organization. (2018). Antibiotic resistance. Available at: https://www.who.int/news-room/factsheets/detail/antibiotic-resistance.
Zubov, P. V., Novikova, V. V. (2015). Sovremennye problemy nauki i obrazovaniia, 5. Available at: http://www.science-education.ru/ru/article/view?id=22672.
Achkasova, T. A. et al. (2012). Uchenye zapiski Tavricheskogo natcionalnogo universiteta im. V. I. Vernadskogo. Ser. Biologiia, khimiia, 25 (64 (1)), 21–28.
Semenza, J. C., Lindgren, E., Balkanyi, L., Espinosa, L., Almqvist, M. S., Penttinen, P., Rocklöv, J. (2016). Determinants and Drivers of Infectious Disease Threat Events in Europe. Emerg. Information Display, 22 (4), 581–589. doi: https://doi.org/10.3201/eid2204.151073.
Vorobey, E., Voronkova, O., Sirokvash, O., Vinnikov, A. (2014). Visnyk Lvivskoho universytetu. Seriia biolohichna, 64, 52–67. Available at: http://er.nau.edu.ua/handle/NAU/37985.
Lazarev, E. V., Vorobey, E. S., Voronkova, O. S. (2014). Visnyk problem biolohii i medytsyny, 3 (2 (111)), 275–278. Available at: https://vpbm.com.ua/ua/vpbm-2014-03-2/6830.
Olefir, Yu. V., Medunitsyn, N. V., Avdeeva, J. I. et al. (2016). BYOpreparaty. Profilaktika, diahnostika, lechenie, 16 (2), 67–77. Available at: https://www.biopreparations.ru/jour/article/view/45/94#.
Bondarev, B. P., Volhin, A. R., Mosiahin, V. D., Obukhov, Yu. I., Shevtsov, V. A. (2012). Vedomosti nauchnogo tcentra ekspertizy sredstv meditcinskogo primeneniia, 2, 22–25.
Diachenko, A. G. (2012). Klinichna imunolohiia. Alerholohiia. Infektolohiia, 7 (56), 20-28. Available at: https://kiai.com.ua/ua/archive/2012/7%2856%29/pages-20-28/suchasni-vakcini-dlya-suchasnoyi-lyudini.
Volianskii, Yu. L., Hrytsenko, I. S., Shirobokov, V. P. (2004). Vyvchennia spetsyfichnoi aktyvnosti protymikrobnykh likarskykh zasobiv. Kyiv: Zdorovie, 38.
Clokie, M. R. J., Kropinski, A. (2009). Bacteriophages. Methods and Protocols. Vol. 1. Isolation, Characterization and Interactions. Humana Press, 301.
Pulcherovskaia, L. P., Sadrtdinova, H. R., Sverkalova, D. H. (2019). Aktualnye voprosy veterinarnoi biologii, 1 (41), 12–16. doi: https://doi.org/10.24411/2074-5036-2019-10007.
Paul, V. D., Sundarrajan, S., Rajagopalan, S. S. et al. (2011). Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection. BMC Microbiol., 31-11, 195. doi: https://doi.org/10.24411/2074-5036-2019-10007.
Henein, A. (2013). What are the Limitations on the Wider Therapeutic use of Phage? Bacteriophage, 3 (2), e24872-1–e24872-7. doi: https://doi.org/10.4161/bact.24872.
Copyright (c) 2020 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).